LUMOS PHARMA INC. - C

Lumos Pharma to Participate in Upcoming Investor Conferences

10 11月 2021 16:06:38 条件 Nasdaq GlobeNewswire

Lumos Pharma Reports Third Quarter 2021 Financial Results and Provides Clinical Updates

03 11月 2021 15:01:01 条件 Nasdaq GlobeNewswire

Lumos Pharma to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021

21 10月 2021 15:05:01 条件 Nasdaq GlobeNewswire

Lumos Pharma to Participate in September Investor Conferences

02 9月 2021 07:00:01 条件 Nasdaq GlobeNewswire

Lumos Pharma Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Updates

05 8月 2021 07:00:02 条件 Nasdaq GlobeNewswire

Lumos Pharma Announces Industry Veteran, David B. Karpf, MD, has Joined the Company as Chief Medical Officer

03 8月 2021 07:00:01 条件 Nasdaq GlobeNewswire

Lumos Pharma Announces the Promotion of COO and Chief Scientific Officer, John McKew, PhD, to President

02 8月 2021 07:00:01 条件 Nasdaq GlobeNewswire

Lumos Pharma Appoints Pediatric Endocrinologist Experienced in Clinical Research and Pharmaceutical Development, Mark Bach, M.D., Ph.D., to Clinical Scientific Advisory Board

26 7月 2021 15:18:40 条件 Nasdaq GlobeNewswire

Lumos Pharma to Report Second Quarter 2021 Financial Results and Host Conference Call on August 5, 2021

22 7月 2021 07:00:04 条件 Nasdaq GlobeNewswire

Lumos Pharma Announces Clinical Updates

20 7月 2021 15:01:00 条件 Nasdaq GlobeNewswire

Lumos Pharma Announces OraGrowtH212 Trial of LUM-201 in PGHD Is Open for Enrollment

28 6月 2021 07:00:00 条件 Nasdaq GlobeNewswire

Lumos Pharma to Participate in the Jefferies Virtual Healthcare Conference

19 5月 2021 08:00:02 条件 Nasdaq GlobeNewswire

Lumos Pharma to Participate in the Oppenheimer Rare & Orphan Disease Summit

13 5月 2021 08:00:01 条件 Nasdaq GlobeNewswire

Lumos Pharma Reports First Quarter 2021 Financial Results and Provides Clinical and Corporate Updates

05 5月 2021 15:01:00 条件 Nasdaq GlobeNewswire

Lumos Pharma to Report First Quarter 2021 Financial Results and Host Conference Call on May 5, 2021

28 4月 2021 08:00:00 条件 Nasdaq GlobeNewswire

Newly Released Data on Three PGHD Patients Treated with LUM-201 in Prior Phase 2 Study To Be Presented in Lumos Pharma Key Opinion Leader Webinar

27 4月 2021 07:00:01 条件 Nasdaq GlobeNewswire

Lumos Pharma Announces Retirement of Carl Langren and Names Lori Lawley Chief Financial Officer in Planned Succession

20 4月 2021 15:05:00 条件 Nasdaq GlobeNewswire

Lumos Pharma to Host Key Opinion Leader Event on LUM-201 for the Treatment of Pediatric Growth Hormone Deficiency

14 4月 2021 15:05:00 条件 Nasdaq GlobeNewswire

Data Presented at ENDO 2021 Differentiate LUM-201 from Standard Growth Hormone Secretagogues and Further Support LUM-201’s Potential as a Therapeutic for Pediatric Growth Hormone Deficiency

20 3月 2021 10:00:00 条件 Nasdaq GlobeNewswire

Lumos Pharma to Participate in March 2021 Investor Conferences

11 3月 2021 15:05:00 条件 Nasdaq GlobeNewswire